A Phase I Study to Assess the Tolerability, Safety and Biological Effects of ATR Inhibitor (AZD6738) as a Single Agent and in Combination With Palliative Radiation Therapy in Patients With Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2017
At a glance
- Drugs AZD 6738 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms PATRIOT
- 05 Apr 2017 Early results of the monotherapy dose-escalation phase (part A, n=26), presented at the 108th Annual Meeting of the American Association for Cancer Research.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 05 Oct 2015 Accrual to date is 10% according to United Kingdom Clinical Research Network record.